文献速递先天性心脏病外科心外重症与机械循环支持

Fontan泵:晚期临床前开发

Fontan pump: Advanced preclinical development.
PubMed 文献 · J Thorac Cardiovasc Surg · 2026-08-19

针对缺乏亚肺动脉泵的Fontan循环晚期衰竭问题,开发了适用于青少年和成人的旋转泵,旨在生理性增强全腔静脉肺动脉连接血流。体外模拟循环和血液测试显示,泵在+6至10 mmHg下增加血流,3K RPM时达+18 mmHg,功耗低至1 W,溶血与商用泵相当,无气蚀或抽吸,停转时压差≤1 mmHg。结论认为该泵可安全逆转Fontan悖论,可能预防Fontan衰竭进展。

要点

  • 旋转泵设计用于植入全腔静脉肺动脉连接,生理性增强血流。
  • 体外测试显示泵在+6至10 mmHg下增加血流,3K RPM时达+18 mmHg。
  • 停转时压差≤1 mmHg,无气蚀或抽吸,溶血与商用泵相当。

核心结论

  • Fontan泵可安全逆转Fontan悖论,具有临床可管理的故障安全应急措施。
  • 该技术可能预防保留体循环心室收缩功能患者的Fontan衰竭进展。
  • 作为长期双心室健康维护的外科策略,可能改善单心室心脏病患者的生活质量和寿命。

研究设计与样本

  • 开发适用于青少年和成人的旋转泵,植入以生理性增强全腔静脉肺动脉连接血流。
  • 设计目标包括在广泛性能范围内实现30/70%上腔静脉/下腔静脉流入抽取,设备故障时无梗阻。
  • 在体外Fontan模拟循环回路中使用血液类似物表征流体动力学和血流动力学性能,在血液中表征溶血。

主要发现

  • 泵在+6至10 mmHg下增强全腔静脉肺动脉连接血流(上腔静脉/下腔静脉流入;左肺动脉/右肺动脉流出),3K RPM时范围至+18 mmHg。
  • 性能在广泛心输出量范围内一致,+6 mmHg压升时功耗低至1 W。
  • 溶血与其他商用泵相当,未观察到气蚀或抽吸,停转条件(0 RPM)下压差≤1 mmHg。

临床怎么用

  • 对于保留体循环心室收缩功能的Fontan衰竭患者,该泵可能作为长期双心室健康维护的外科策略。
  • 设备故障时停转压差≤1 mmHg,临床可管理,提供了故障安全应急。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Late Fontan failure and attrition is an increasingly prevalent problem for which there is no primary therapy. A Fontan circulation is a circulation that lacks a subpulmonary pump. We are developing a technology that can safely and reliably restore subpulmonary pump function in a Fontan circulation to reverse the Fontan paradox and maintain normal circulatory health. METHODS: A rotary pump scaled for adolescent and adult use was developed for implantation to physiologically augment flow in the total cavopulmonary connection. Design objectives included 30/70% superior vena cava/inferior vena cava inflow draw over a broad range of performance, and no obstruction in the event of device failure. Hydrodynamic and hemodynamic performance were characterized in vitro in a Fontan mock circulatory loop using blood analog. Hemolysis was characterized in blood. RESULTS: The pump augments total cavopulmonary connection flow (superior vena cava/inferior vena cava inflow; left pulmonary artery/right pulmonary artery outflow) at +6 to 10 mm Hg, ranging to +18 mm Hg at 3K RPM. Performance is consistent over a wide range of cardiac output. Power requirement is low (1 W) at +6 mm Hg pressure rise. Hemolysis is comparable with other commercially available pumps. Cavitation or suction was not observed. In the stalled condition (0 RPM), gradient is ≤1 mm Hg. CONCLUSIONS: A Fontan pump can safely reverse the Fontan paradox. Features include a fail-safe contingency that is clinically manageable. The technology may prevent progression of Fontan failure in the setting of preserved systemic ventricular systolic function. As a surgical strategy of long-term biventricular health maintenance, it may improve quality and duration of life for patients with single ventricle heart disease.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Rodefeld MD, Figliola R, Conover T, et al. Fontan pump: Advanced preclinical development. J Thorac Cardiovasc Surg. 2026. PMID: 42617684. doi:10.1016/j.jtcvs.2026.08.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。